Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,401
archived clinical trials in
Alzheimer Disease

Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Status: Enrolling
Updated:  4/2/2018
Quillen College of Medicine, East TN State University
mi
from
Johnson City, TN
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Status: Enrolling
Updated: 4/2/2018
Quillen College of Medicine, East TN State University
mi
from
Johnson City, TN
Click here to add this to my saved trials
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Status: Enrolling
Updated:  4/2/2018
Vanderbilt Univeristy School of Medicine
mi
from
Nashville, TN
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Status: Enrolling
Updated: 4/2/2018
Vanderbilt Univeristy School of Medicine
mi
from
Nashville, TN
Click here to add this to my saved trials
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Status: Enrolling
Updated:  4/2/2018
UT Southwestern Medical Center
mi
from
Dallas, TX
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Status: Enrolling
Updated: 4/2/2018
UT Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Status: Enrolling
Updated:  4/2/2018
Radiant Research, Inc.
mi
from
Murray, UT
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Status: Enrolling
Updated: 4/2/2018
Radiant Research, Inc.
mi
from
Murray, UT
Click here to add this to my saved trials
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Status: Enrolling
Updated:  4/2/2018
University of Utah School of Medicine
mi
from
Salt Lake City, UT
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Status: Enrolling
Updated: 4/2/2018
University of Utah School of Medicine
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Status: Enrolling
Updated:  4/2/2018
The Memory Clinic
mi
from
Bennington, VT
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Status: Enrolling
Updated: 4/2/2018
The Memory Clinic
mi
from
Bennington, VT
Click here to add this to my saved trials
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Status: Enrolling
Updated:  4/2/2018
National Clinical Research - Norfolk, Inc.
mi
from
Norfolk, VA
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Status: Enrolling
Updated: 4/2/2018
National Clinical Research - Norfolk, Inc.
mi
from
Norfolk, VA
Click here to add this to my saved trials
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Status: Enrolling
Updated:  4/2/2018
National Clinical Research - Richmond, Inc.
mi
from
Richmond, VA
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Status: Enrolling
Updated: 4/2/2018
National Clinical Research - Richmond, Inc.
mi
from
Richmond, VA
Click here to add this to my saved trials
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Status: Enrolling
Updated:  4/2/2018
Blue Ridge Research Center
mi
from
Roanoke, VA
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Status: Enrolling
Updated: 4/2/2018
Blue Ridge Research Center
mi
from
Roanoke, VA
Click here to add this to my saved trials
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Status: Enrolling
Updated:  4/2/2018
Veterans Affairs Puget Sound Health Care System
mi
from
Seattle, WA
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Status: Enrolling
Updated: 4/2/2018
Veterans Affairs Puget Sound Health Care System
mi
from
Seattle, WA
Click here to add this to my saved trials
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Status: Enrolling
Updated:  4/2/2018
University of California at San Francisco
mi
from
San Francisco, CA
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Status: Enrolling
Updated: 4/2/2018
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Status: Enrolling
Updated:  4/2/2018
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Status: Enrolling
Updated: 4/2/2018
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Status: Enrolling
Updated:  4/2/2018
New York Univ. Medical Center
mi
from
New York, NY
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Status: Enrolling
Updated: 4/2/2018
New York Univ. Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Status: Enrolling
Updated:  4/2/2018
Texas Neurology, PA
mi
from
Dallas, TX
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Status: Enrolling
Updated: 4/2/2018
Texas Neurology, PA
mi
from
Dallas, TX
Click here to add this to my saved trials
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Status: Enrolling
Updated:  4/2/2018
Diagnostic Research Group
mi
from
San Antonio, TX
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Status: Enrolling
Updated: 4/2/2018
Diagnostic Research Group
mi
from
San Antonio, TX
Click here to add this to my saved trials
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Status: Enrolling
Updated:  4/2/2018
mi
from
Darlinghurst,
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Status: Enrolling
Updated: 4/2/2018
mi
from
Darlinghurst,
Click here to add this to my saved trials
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Status: Enrolling
Updated:  4/2/2018
Arizona Health Sciences Center
mi
from
Tucson, AZ
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Status: Enrolling
Updated: 4/2/2018
Arizona Health Sciences Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Status: Enrolling
Updated:  4/2/2018
Brain Matters Research
mi
from
Delray Beach, FL
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Status: Enrolling
Updated: 4/2/2018
Brain Matters Research
mi
from
Delray Beach, FL
Click here to add this to my saved trials
Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD
A Randomized, Open-Label, Multiple Dose Clinical Pharmacology Study of Two Doses of a Selective p38 MAP Kinase Inhibitor, VX-745 in Patients With Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) or With Mild AD
Status: Enrolling
Updated:  4/2/2018
Parexel International
mi
from
Glendale, CA
Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD
A Randomized, Open-Label, Multiple Dose Clinical Pharmacology Study of Two Doses of a Selective p38 MAP Kinase Inhibitor, VX-745 in Patients With Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) or With Mild AD
Status: Enrolling
Updated: 4/2/2018
Parexel International
mi
from
Glendale, CA
Click here to add this to my saved trials
Rasagiline Rescue in Alzheimer's Disease Clinical Trial
A 24-week, Three-site, Randomized, Double Blind, Placebo Controlled, Parallel Group, Proof-of-concept Study to Evaluate Rasagiline in the Regional Brain Metabolism on FDG PET in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  4/3/2018
Cleveland Clinic Lou Ruvo Center for Brain Health
mi
from
Las Vegas, NV
Rasagiline Rescue in Alzheimer's Disease Clinical Trial
A 24-week, Three-site, Randomized, Double Blind, Placebo Controlled, Parallel Group, Proof-of-concept Study to Evaluate Rasagiline in the Regional Brain Metabolism on FDG PET in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 4/3/2018
Cleveland Clinic Lou Ruvo Center for Brain Health
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Rasagiline Rescue in Alzheimer's Disease Clinical Trial
A 24-week, Three-site, Randomized, Double Blind, Placebo Controlled, Parallel Group, Proof-of-concept Study to Evaluate Rasagiline in the Regional Brain Metabolism on FDG PET in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  4/3/2018
The Cleveland Clinic, Main Campus
mi
from
Cleveland, OH
Rasagiline Rescue in Alzheimer's Disease Clinical Trial
A 24-week, Three-site, Randomized, Double Blind, Placebo Controlled, Parallel Group, Proof-of-concept Study to Evaluate Rasagiline in the Regional Brain Metabolism on FDG PET in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 4/3/2018
The Cleveland Clinic, Main Campus
mi
from
Cleveland, OH
Click here to add this to my saved trials
Rasagiline Rescue in Alzheimer's Disease Clinical Trial
A 24-week, Three-site, Randomized, Double Blind, Placebo Controlled, Parallel Group, Proof-of-concept Study to Evaluate Rasagiline in the Regional Brain Metabolism on FDG PET in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  4/3/2018
Cleveland Clinic Lakewood Hospital
mi
from
Lakewood, OH
Rasagiline Rescue in Alzheimer's Disease Clinical Trial
A 24-week, Three-site, Randomized, Double Blind, Placebo Controlled, Parallel Group, Proof-of-concept Study to Evaluate Rasagiline in the Regional Brain Metabolism on FDG PET in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 4/3/2018
Cleveland Clinic Lakewood Hospital
mi
from
Lakewood, OH
Click here to add this to my saved trials
Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease
Interventional, Open-label, Positron Emission Tomography (PET) Study Investigating the Brain Receptor Occupancy of Idalopirdine in Patients With Alzheimer's Disease
Status: Enrolling
Updated:  4/3/2018
Johns Hopkins Hospital
mi
from
Baltimore, MD
Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease
Interventional, Open-label, Positron Emission Tomography (PET) Study Investigating the Brain Receptor Occupancy of Idalopirdine in Patients With Alzheimer's Disease
Status: Enrolling
Updated: 4/3/2018
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Early Markers of Cognitive Change and Alzheimer s Disease
Early Markers of Cognitive Change and Alzheimer's Disease: A Propsective Study of the Effects of Aging on Cognition and Brain Pathology
Status: Enrolling
Updated:  4/4/2018
National Institute of Aging, Clinical Research Unit
mi
from
Baltimore, MD
Early Markers of Cognitive Change and Alzheimer s Disease
Early Markers of Cognitive Change and Alzheimer's Disease: A Propsective Study of the Effects of Aging on Cognition and Brain Pathology
Status: Enrolling
Updated: 4/4/2018
National Institute of Aging, Clinical Research Unit
mi
from
Baltimore, MD
Click here to add this to my saved trials
In Vivo Imaging of Therapeutic Electric Current Flow
In Vivo Imaging of Therapeutic Electric Current Flow
Status: Enrolling
Updated:  4/4/2018
University of Florida
mi
from
Gainesville, FL
In Vivo Imaging of Therapeutic Electric Current Flow
In Vivo Imaging of Therapeutic Electric Current Flow
Status: Enrolling
Updated: 4/4/2018
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated:  4/27/2018
Clinical Research Facility
mi
from
Tuscaloosa, AL
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated: 4/27/2018
Clinical Research Facility
mi
from
Tuscaloosa, AL
Click here to add this to my saved trials
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated:  4/27/2018
Clinical Research Facility
mi
from
Costa Mesa, CA
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated: 4/27/2018
Clinical Research Facility
mi
from
Costa Mesa, CA
Click here to add this to my saved trials
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated:  4/27/2018
Clinical Research Facility
mi
from
Orange, CA
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated: 4/27/2018
Clinical Research Facility
mi
from
Orange, CA
Click here to add this to my saved trials
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated:  4/27/2018
Clinical Research Facility
mi
from
Redlands, CA
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated: 4/27/2018
Clinical Research Facility
mi
from
Redlands, CA
Click here to add this to my saved trials
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated:  4/27/2018
Clinical Research Facility
mi
from
Bradenton, FL
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated: 4/27/2018
Clinical Research Facility
mi
from
Bradenton, FL
Click here to add this to my saved trials
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated:  4/27/2018
Clinical Research Facility
mi
from
Hialeah, FL
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated: 4/27/2018
Clinical Research Facility
mi
from
Hialeah, FL
Click here to add this to my saved trials
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated:  4/27/2018
Clinical Research Facility
mi
from
Miami Springs, FL
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated: 4/27/2018
Clinical Research Facility
mi
from
Miami Springs, FL
Click here to add this to my saved trials
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated:  4/27/2018
Clinical Research Facility
mi
from
Miami, FL
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated: 4/27/2018
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated:  4/27/2018
Clinical Research Facility
mi
from
North Miami, FL
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated: 4/27/2018
Clinical Research Facility
mi
from
North Miami, FL
Click here to add this to my saved trials
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated:  4/27/2018
Clinical Research Facility
mi
from
Orange City, FL
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated: 4/27/2018
Clinical Research Facility
mi
from
Orange City, FL
Click here to add this to my saved trials
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated:  4/27/2018
Clinical Research Facility
mi
from
Atlanta, GA
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated: 4/27/2018
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated:  4/27/2018
Clinical Research Facility
mi
from
Suwanee, GA
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated: 4/27/2018
Clinical Research Facility
mi
from
Suwanee, GA
Click here to add this to my saved trials
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated:  4/27/2018
Clinical Research Facility
mi
from
Quincy, MA
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated: 4/27/2018
Clinical Research Facility
mi
from
Quincy, MA
Click here to add this to my saved trials
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated:  4/27/2018
Clinical Research Facility
mi
from
Toms River, NJ
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated: 4/27/2018
Clinical Research Facility
mi
from
Toms River, NJ
Click here to add this to my saved trials
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated:  4/27/2018
Clinical Research Facility
mi
from
Brooklyn, NY
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated: 4/27/2018
Clinical Research Facility
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated:  4/27/2018
Clinical Research Facility
mi
from
New Hyde Park, NY
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated: 4/27/2018
Clinical Research Facility
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated:  4/27/2018
Clinical Research Facility
mi
from
Hickory, NC
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated: 4/27/2018
Clinical Research Facility
mi
from
Hickory, NC
Click here to add this to my saved trials
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated:  4/27/2018
Clinical Research Facility
mi
from
Raleigh, NC
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated: 4/27/2018
Clinical Research Facility
mi
from
Raleigh, NC
Click here to add this to my saved trials
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated:  4/27/2018
Clinical Research Facility
mi
from
Waukesha, WI
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated: 4/27/2018
Clinical Research Facility
mi
from
Waukesha, WI
Click here to add this to my saved trials
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated:  4/27/2018
Clinical Research Facility
mi
from
Lakewood, CA
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated: 4/27/2018
Clinical Research Facility
mi
from
Lakewood, CA
Click here to add this to my saved trials
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated:  4/27/2018
Clinical Research Facility
mi
from
Sarasota, FL
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated: 4/27/2018
Clinical Research Facility
mi
from
Sarasota, FL
Click here to add this to my saved trials
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated:  4/27/2018
Clinical Research Facility
mi
from
Charlotte, NC
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated: 4/27/2018
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated:  4/27/2018
Clinical Research Facility
mi
from
Dallas, TX
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated: 4/27/2018
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated:  4/27/2018
Clinical Research Facility
mi
from
Saint Louis, MO
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated: 4/27/2018
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated:  4/27/2018
Study Site
mi
from
Burgas,
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Status: Enrolling
Updated: 4/27/2018
Study Site
mi
from
Burgas,
Click here to add this to my saved trials